Steroid cell tumors account for less than 0.1% of all ovarian tumors. There are three steroid cell tumor subtypes: steroid cell tumor not otherwise specified (NOS), stromal luteoma and Leydig cell tumor. Steroid cell tumor, NOS, is the most common type and has malignant potential. This report describes a case of an ovarian steroid cell tumor, NOS. A 35-year-old woman visited hospital with the complaint of metrorrhagia. Physical examination revealed increased pubic hair. Transvaginal ultrasound indentified a 4.9 × 3.4 cm, well-circumscribed and solid left ovarian tumor. After laparoscopic left oophorectomy, the tumor was revealed as an ovarian steroid cell tumor, NOS. During the laparoscopic surgery, tumor ruptured. Complete surgical staging was performed and no evidence of metastasis was found. Gonadotropin releasing hormone agonist was administered monthly for 6 months. The patient has had no evidence of recurrence for 43 months. 
Introduction
Steroid cell tumors are rare sex cord-stromal tumors of the ovary. These tumors were previously classified as 
Case Report
A 35-year-old Korean woman (gravida 5, para 2) visited hospital with the complaint of metrorrhagia. The patient reported that she had been suffering from metrorrhagia since 7 months ago. Her past medical history revealed left salpingectomy due to ectopic pregnancy. She was 154 cm in height and 70 kg in weight. Her body mass index was 29.5 and she was overweight. Physical examination revealed increased pubic hair and normal external genitalia.
Transvaginal ultrasound indentified a 4.9 × 3.4 cm, well-circumscribed and solid left ovarian tumor (Fig. 1 ). (Fig. 2) . No cellular atypia was noted and mitotic figures were rare (less than 1 per 10 high-power fields). It was diagnosed as steroid cell tumor,
NOS.
Two weeks postoperatively, a computerized tomography (CT) scan and endometrial biopsy were performed and no remarkable findings were found.
As she had completed childbearing, complete surgical staging including peritoneal washing, total abdominal hysterectomy, right salpingo-oophorectomy, appendectomy, bilateral pelvic lymph node dissection and infracolic omentectomy was performed after 4 weeks from the first laparoscopic surgery. Microscopically, no evidence of metastasis was found. As the left ovary rupture at initial laparoscopic surgery, the patient was treated with GnRHa monthly for 6 months. After 43 months, she has had no evidence of recurrence.
Discussion
Steroid cell tumors were previously classified as lipid or lipoid cell tumors. This prior nomenclature was misleading Hormones other than testosterone can be elevated in steroid cell tumors, NOS. Estradiol secretion by these tumors is not uncommon, occurring in 6-23% of patients.
This excess estrogen production can result in menorrhagia and postmenopausal bleeding; in addition, endometrial adenocarcinoma has been described. 4 Our patient presented metrorrhagia, but serum value of estradiol and endometrial biopsy were normal. Steroid cell tumors, NOS, have also been associated with Cushing's syndrome in 6-10% of cases, but approximately 25% of steroid cell tumors, NOS, do not produce hormones. The clinical course of steroid cell tumors of the ovary Wang et al. 2 suggested that GnRHa might be an alternative choice as adjuvant therapy for managing recurrence of ovarian steroid cell tumor. As the tumor ruptured during the first laparoscopic surgery and we could not expect the clinical course, we administered GnRHa in our patient to prevent recurrence on the basis of these evidences.
As far as we know, there is no previously reported case of ovarian steroid cell tumor treated with complete surgical staging followed by GnRHa in Korea (Table 1) . Our patient has had no evidence of recurrence for 43 months. GnRHa should be considered as one of adjuvant therapy in ovarian steroid cell tumors.
